US equities |
INTC $92.07 ▲+0.00% SNDK $1,330.05 ▲+0.00% MU $934.27 ▲+0.00% NVDA $213.66 ▲+0.00% AMZN $243.79 ▲+0.00% GOOGL $283.82 ▲+0.00% AAPL $348.91 ▲+0.00% SKHY $162.09 ▲+0.00%
FinancialContent

Articles published by 4D Molecular Therapeutics, Inc.

< Previous 1 2 3 4 Next >
News headline image
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Announces Presentations at Upcoming Retina Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT to Participate in Upcoming Investor Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Announces Presentations at ARVO 2024 Annual Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
News headline image
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
< Previous 1 2 3 4 Next >